ArticleAmerican journal of translational research2026
Lower serum SFRP5 levels are associated with carotid atherosclerosis in patients with essential hypertension.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the variation in serum secreted frizzled-related protein 5 (SFRP5) levels among individuals with essential hypertension and its association with carotid atherosclerosis.
methods297 subjects were included: 77 with stage 1 hypertension, 73 with stage 2, 67 with stage 3, and 80 normotensive controls. Logistic regression analyses alongside receiver operating characteristic (ROC) curve examinations were used to determine the independent relationship and predictive significance of SFRP5 in relation to carotid atherosclerosis. The primary outcome measure was serum SFRP5 level. Secondary outcome measures included levels of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), carotid intima-media thickness (CIMT), and incidence of carotid plaque.
resultsSerum SFRP5 levels decreased significantly with increasing hypertension severity and were lower in patients with carotid atherosclerosis (P<0.001). A strong inverse relationship was found between SFRP5 levels and carotid atherosclerosis (r = -0.67, P<0.001). Regression analysis revealed SFRP5 was an independent protective factor (adjusted OR = 0.673, 95% CI: 0.585-0.774, P<0.001) after adjusting for age, sex, body mass index (BMI), low-density lipoprotein cholesterol (LDL-C), and hypertension grade. SFRP5's predictive capability for carotid atherosclerosis was indicated by an area under ROC curve of 0.902.
conclusionLower serum SFRP5 levels are associated with hypertension severity and heightened risk of carotid atherosclerosis in hypertensive patients. SFRP5 may be a biomarker for risk assessment and may also represent a promising therapeutic target. Additional studies are required to validate these results and unravel the underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.